Pharma Industry News

STAT+: Q&A: Why medical AI and value-based care may be made for each other

At last count, the Food and Drug Administration has authorized 950 medical devices that use artificial intelligence and machine learning. But far fewer have made a significant impact on patient care in the United States.

For medical AI developers like James Zou, that’s a problem. The Stanford professor is invested in getting effective medical machine learning — including some of his own, FDA-cleared algorithms — adopted by health systems.

In two recent papers, Zou examined the clinical adoption of medical AI devices, finding that a tiny minority of FDA-authorized devices are being reimbursed at any kind of scale — and delving into different models for how health systems could pay for medical AI.
Continue to STAT+ to read the full story…

At last count, the Food and Drug Administration has authorized 950 medical devices that use artificial intelligence and machine learning. But far fewer have made a significant impact on patient care in the United States.

For medical AI developers like James Zou, that’s a problem. The Stanford professor is invested in getting effective medical machine learning — including some of his own, FDA-cleared algorithms — adopted by health systems.

In two recent papers, Zou examined the clinical adoption of medical AI devices, finding that a tiny minority of FDA-authorized devices are being reimbursed at any kind of scale — and delving into different models for how health systems could pay for medical AI.

Continue to STAT+ to read the full story…

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]